title: Effect of central nervous system medication use on decline in cognition in community-dwelling older adults: findings from the Health, Aging And Body Composition Study.
abstract: OBJECTIVE
  To evaluate whether combined use of multiple central nervous system (CNS) medications over time is associated with cognitive change.
  
  
  METHODS
  Longitudinal cohort study.
  
  
  METHODS
  Pittsburgh, Pennsylvania, and Memphis, Tennessee.
  
  
  METHODS
  Two thousand seven hundred thirty-seven healthy adults (aged > or =65) enrolled in the Health, Aging and Body Composition study without baseline cognitive impairment (modified Mini-Mental State Examination (3MS) score > or =80).
  
  
  METHODS
  CNS medication (benzodiazepine- and opioid-receptor agonists, antipsychotics, antidepressants) use, duration, and dose were determined at baseline (Year 1) and Years 3 and 5. Cognitive function was measured using the 3MS at baseline and Years 3 and 5. The outcome variables were incident cognitive impairment (3MS score <80) and cognitive decline (> or =5-point decline on 3MS). Multivariable interval-censored survival analyses were conducted.
  
  
  RESULTS
  By Year 5, 7.7% of subjects had incident cognitive impairment; 25.2% demonstrated cognitive decline. CNS medication use increased from 13.9% at baseline to 15.3% and 17.1% at Years 3 and 5, respectively. It was not associated with incident cognitive impairment (adjusted hazard ratio (adj HR)=1.11, 95% confidence interval (CI)=0.73-1.69) but was associated with cognitive decline (adj HR 1.37, 95% CI=1.11-1.70). Longer duration (adj HR=1.39, CI=1.08-1.79) and higher doses (>3 standardized daily doses) (adj HR=1.87, 95% CI=1.25-2.79) of CNS medications suggested greater risk of cognitive decline than with nonuse.
  
  
  CONCLUSIONS
  Combined use of CNS medications, especially at higher doses, appears to be associated with cognitive decline in older adults. Future studies must explore the effect of combined CNS medication use on vulnerable older adults.
authors.affiliation: Department of Medicine, University of Pittsburgh, Pennsylvania 15213, USA. rmw27@pitt.edu
authors.forename: Rollin M
authors.initials: RM
authors.lastname: Wright
authors.forename: Yazan F
authors.initials: YF
authors.lastname: Roumani
authors.forename: Robert
authors.initials: R
authors.lastname: Boudreau
authors.forename: Anne B
authors.initials: AB
authors.lastname: Newman
authors.forename: Christine M
authors.initials: CM
authors.lastname: Ruby
authors.forename: Stephanie A
authors.initials: SA
authors.lastname: Studenski
authors.forename: Ronald I
authors.initials: RI
authors.lastname: Shorr
authors.forename: Douglas C
authors.initials: DC
authors.lastname: Bauer
authors.forename: Eleanor M
authors.initials: EM
authors.lastname: Simonsick
authors.forename: Sarah N
authors.initials: SN
authors.lastname: Hilmer
authors.forename: Joseph T
authors.initials: JT
authors.lastname: Hanlon
mesh_terms: D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects; D001921:Brain / Q000187:drug effects*; D003071:Cognition / Q000187:drug effects; D003072:Cognition Disorders / Q000139:chemically induced*; D005260:Female; D058787:GABA-A Receptor Antagonists; D006801:Humans; D008297:Male; D009292:Narcotic Antagonists; D013997:Time Factors
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D058787:GABA-A Receptor Antagonists; D009292:Narcotic Antagonists